Evidence map›Paper›PMID 38984940›Full record

Trial reportJournal of neurotrauma2025

Evaluating and Updating the IMPACT Model to Predict Outcomes in Two Contemporary North American Traumatic Brain Injury Cohorts.

Naoki Takegami, Abel Torres-Espin, Yoshihito Imagawa, Itsunori Watanabe, Susan Rowell, Martin Schreiber, Adam R Ferguson, H E Hinson

Abstract readMulticenter StudyRandomized Controlled TrialClinical Trial, Phase II
In one paragraph

Trial report in Journal of neurotrauma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Naoki TakegamiDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Abel Torres-EspinSchool of Public Health Sciences, University of Waterloo, Waterloo, Canada.
Yoshihito ImagawaDepartment of Chemistry and Biomolecular Science, Biomolecular Science Course, Faculty of Engineering, Gifu University, Gifu, Japan.
Itsunori WatanabeDepartment of Computer Science and Engineering, School of Fundamental Science and Engineering, Waseda University, Tokyo, Japan.
Susan RowellDepartment of Surgery, Oregon Health & Science University, Portland, Oregon, USA.
Martin SchreiberDonald D. Trunkey Center for Civilian and Combat Casualty Care, Oregon Health & Science University, Portland, Oregon, USA.
Adam R FergusonDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
H E HinsonDepartment of Neurology, University of California, San Francisco, California, USA.ORCID 0000-0003-1598-9782

Funding

Predictors of Low-risk Phenotypes after Traumatic Brain Injury Incorporating Proteomic Biomarker Signatures.K23NS110828 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HINSON, HOLLY ELAINE · 2020 to 2024
$1.0M
NINDS NIH HHS K23 NS110828
6 · The paper itself

Abstract

The International Mission on Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) model is a widely recognized prognostic model applied after traumatic brain injury (TBI). However, it was developed with patient cohorts that may not reflect modern practice patterns in North America. We analyzed data from two sources: the placebo arm of the phase II double-blinded, multicenter, randomized controlled trial Prehospital Tranexamic Acid for TBI (TXA) cohort and an observational cohort with similar inclusion/exclusion criteria (Predictors of Low-risk Phenotypes after Traumatic Brain Injury Incorporating Proteomic Biomarker Signatures [PROTIPS] cohort). All three versions of the IMPACT model-core, extended, and laboratory-were evaluated for 6-month mortality (Glasgow Outcome Scale Extended [GOSE] = 1) and unfavorable outcomes (GOSE = 1-4). Calibration (intercept and slope) and discrimination (area under the receiver operating characteristic curve [ROC-AUC]) were used to assess model performance. We then compared three model updating methods-recalibration in the large, logistic recalibration, and coefficient update-with the best update method determined by likelihood ratio tests. In our calibration analysis, recalibration improved both intercepts and slopes, indicating more accurate predicted probabilities when recalibration was done. Discriminative performance of the IMPACT models, measured by AUC, showed mortality prediction ROCs between 0.61 and 0.82 for the TXA cohort, with the coefficient updated Lab model achieving the highest at 0.84. Unfavorable outcomes had lower AUCs, ranging from 0.60 to 0.79. Similarly, in the PROTIPS cohort, AUCs for mortality ranged from 0.75 to 0.82, with the coefficient updated Lab model also showing superior performance (AUC 0.84). Unfavorable outcomes in this cohort presented AUCs from 0.67 to 0.73, consistently lower than mortality predictions. The closed testing procedure using likelihood ratio tests consistently identified the coefficient update model as superior, outperforming the original and recalibrated models across all cohorts. In our comprehensive evaluation of the IMPACT model, the coefficient updated models were the best performing across all cohorts through a structured closed testing procedure. Thus, standardization of model updating procedures is needed to reproducibly determine the best performing versions of IMPACT that reflect the specific characteristics of a dataset.

Indexed as

Brain Injuries, TraumaticAdultAntifibrinolytic AgentsBiomarkersCohort StudiesDouble-Blind MethodFemaleHumansMaleMiddle AgedNorth AmericaPrognosisTranexamic AcidAntifibrinolytic AgentsBiomarkersTranexamic Acidadult brain injurybiomarkersepidemiologytraumatic brain injury

Identifiers

PMID38984940
PMCPMC12677215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.